Faeth Therapeutics, Inc. (FTH) Earnings History
Net Loss8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Faeth Therapeutics, Inc. (FTH) Earnings Overview
As of November 18, 2026, Faeth Therapeutics, Inc. (FTH) reported trailing twelve-month net income of -$211M, reflecting +30.4% year-over-year growth. The company earned $-8.18 per diluted share over the past four quarters.
Looking at the long-term picture, FTH's historical earnings data spans multiple years. The company achieved its highest annual net income of -$13M in fiscal 2018.
Faeth Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$509M net income), ADCT (-$81M net income, -175.3% margin), IMCR (-$24M net income, -8.9% margin), FTH has comparable earnings metrics. Compare FTH vs IMVT →
FTH Earnings vs Peers
Earnings metrics vs comparable public companies
FTH Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$21M | +30.1% | -$22M | $-16.72 | - | - |
| 2024 | -$30M | +11.6% | -$32M | $-24.01 | - | - |
| 2023 | -$34M | +29.8% | -$37M | $-24.40 | - | - |
| 2022 | -$49M | -32.1% | -$49M | $-31.65 | - | - |
| 2021 | -$37M | -83.1% | -$37M | $-26.56 | - | - |
| 2020 | -$20M | -20.1% | -$19M | $-13.21 | - | - |
| 2019 | -$17M | -28.4% | -$12M | $-14.01 | - | - |
| 2018 | -$13M | - | -$13M | $-11.49 | - | - |
Download Data
Export FTH earnings history in CSV or JSON format
Free sign-in required to download data
FTH Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
FTH — Frequently Asked Questions
Quick answers to the most common questions about buying FTH stock.
What is FTH earnings per share (EPS)?
FTH trailing twelve-month (TTM) diluted EPS is $-8.18, reflecting +30.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is Faeth Therapeutics, Inc.'s net income?
Faeth Therapeutics, Inc. (FTH) trailing twelve-month net income is $-211M as of 2025. Earnings grew +30.4% year-over-year.
Is FTH profitable?
FTH is not currently profitable on a TTM basis, reporting a net loss of $-211M. Net margin is N/A. Investors should monitor for a return to profitability.
What is FTH's earnings growth rate?
FTH compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are FTH's profit margins?
Faeth Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -74.0%.
Is FTH growing earnings?
Yes, FTH earnings are accelerating — EPS growth of +30.4% exceeds the 5-year CAGR of N/A. TTM net income reached $-211M. Earnings momentum is strengthening.
What was FTH's best earnings year?
Faeth Therapeutics, Inc.'s highest annual net income on record is $-13M, achieved in fiscal year 2018. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were FTH's earnings last quarter?
FTH's most recent reported quarter was Q3 2026. Net income was $-20M with diluted EPS of $-0.79. For a full breakdown of all quarters, see the quarterly earnings table on this page.